Cue Biopharma
CUE
50 hedge funds and large institutions have $10.5M invested in Cue Biopharma in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 28 closing their positions.
200% more call options, than puts
Call options by funds: $24K | Put options by funds: $8K
0.01% more ownership
Funds ownership: 0.95% → 0.95% (+0.01%)
33% less funds holding
Funds holding: 75 → 50 (-25)
38% less capital invested
Capital invested by funds: $17.1M → $10.5M (-$6.59M)
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
89% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
Bleichroeder LP
New York
|
+$1.54M |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$97.7K |
| 3 |
GLA
Good Life Advisors
Reading,
Pennsylvania
|
+$54.1K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$20K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
Monaco Asset Management
Monaco
|
-$314K |
| 2 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$191K |
| 3 |
Goldman Sachs
New York
|
-$179K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$153K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$148K |
CUE Hedge Fund Activity: Q3 2024 in Review
50 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q3 2024, worth a combined $10.5M — down 38% from $17.1M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of CUE and 3 opened new positions — a net loss of 25 holders — while 17 trimmed existing stakes and 8 added.
The largest buyer was Bleichroeder LP, adding an estimated $1.54M. The largest seller was Monaco Asset Management, exiting entirely with an estimated $314K sold.
- 50 institutional investors held Cue Biopharma (CUE) as of Q3 2024, down from 75 in Q2 2024.
- Funds reported $10.5M of Cue Biopharma stock for Q3 2024, down 38% quarter-over-quarter.
- 3 funds opened new Cue Biopharma positions in Q3 2024 and 28 closed out, a net change of -25 holders.
- The largest Cue Biopharma buyer in Q3 2024 was Bleichroeder LP, an estimated $1.54M added.
- The largest Cue Biopharma seller in Q3 2024 was Monaco Asset Management, an estimated $314K sold.
Based on aggregated 13F filings for Q3 2024.